Scientific Symposium on Bone Marrow Failure and Myelodysplastic Syndromes: From Discovery to Future Strategies

Saturday, October 24, 2026, 6:00 PM - Tuesday, October 27, 2026, 3:00 PM, St. Jude Children's Research Hospital

St. Jude Children's Research Hospital will host the Scientific Symposium on Bone Marrow Failure and Myelodysplastic Syndromes: From Discovery to Future Strategies on October 25–27, 2026, in partnership with the North American Pediatric Aplastic Anemia Consortium (NAPAAC). NAPAAC is a research consortium established in 2011 to advance research and therapies in pediatric bone marrow failure and myelodysplastic syndromes.

About the Symposium

Bone marrow failure (BMF) disorders and myelodysplastic syndromes (MDS) represent over 20 disease entities with at least 150 causative genes. Despite rapid progress in genetic diagnostics, developing targeted therapies and deploying effective surveillance remain a critical challenge.

This symposium brings together >60 academic centers who are members of the NAPAAC consortium. In addition, global leaders in bone marrow failure from Europe, Asia, South America, and Australia will share discoveries and clinical insights on genetics, transplantation, gene therapy, predisposition syndromes, and emerging treatment strategies.

Program Highlights

Sunday, October 25 (from 3pm):

Opening session on international collaboration and patient advocacy.

Monday, October 26 (8am – 6pm) and Tuesday, October 27 (8am – 1pm):

Scientific sessions on hematopoiesis, genomics, disease mechanisms, and emerging therapies including novel transplant strategies and genome engineering. Poster session to showcase basic, translational and clinical research within NAPAAC.

Networking and Collaboration:

This interactive event provides opportunities to network with peers, engage in strategic discussions on emerging treatment approaches, and connect across the global community. Dedicated time will be offered for NAPAAC working groups to discuss progress and define future priorities.

Registration fees and deadlines:

Registration Type (in person)	Early Bird by August 14, 2026	Late Registration August 14 – October 10, 2026
St. Jude Employee	Free	Free
Invited Speaker	Free	Free
NAPAAC Center - Trainee (student, postdoc, clinical fellow, resident)	Free	$200
NAPAAC Center - Other (including PI, physician, APP, genetic counselor)	$70	$250
St. Jude Affiliate	$70	$250
External: Academic	$400	$500
External: All Others, Including Industry	$800	$1,000

Virtual participation options will be added in August.

St. Jude Children's Research Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

St. Jude Children’s Research Hospital designates this Live Activity for a maximum of 13.00 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ (13.00 hours), Non-Physician Attendance (13.00 hours)

Hotel Accommodations

The Peabody Memphis

149 Union Avenue, Memphis, TN 38103

Group Rate: $199/night

Group Name: St. Jude NAPAAC Scientific Symposium

Reservations: 1-800-PEABODY

Reservation Deadline: October 2, 2026

Please reference the group name when booking to receive the discounted rate.

Booking link: https://reservations.peabodymemphis.com/95096?groupID=5315246

The faculty for this activity are listed below. Click to view the faculty member's financial disclosure information and bio. 

Mitigation of Relevant Financial Relationships

St Jude Children's Research Hospital adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (ie, companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.